CN203389001U - Posterior eye segment transscleral controlled-release administration apparatus - Google Patents
Posterior eye segment transscleral controlled-release administration apparatus Download PDFInfo
- Publication number
- CN203389001U CN203389001U CN201320306408.2U CN201320306408U CN203389001U CN 203389001 U CN203389001 U CN 203389001U CN 201320306408 U CN201320306408 U CN 201320306408U CN 203389001 U CN203389001 U CN 203389001U
- Authority
- CN
- China
- Prior art keywords
- sclera
- electrode
- ultrasonic probe
- electric field
- back segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Electrotherapy Devices (AREA)
Abstract
The utility model discloses a posterior eye segment transscleral controlled-release administration apparatus. The apparatus comprises a drug-loaded sclera hydrated multimer contact lens-type administration device which is disposed in the conjunctival sac; a low-frequency ultrasonic device comprising an ultrasonic probe which covers the flat part of the ciliary body; and an electric field iontophoresis device used for promoting a drug to enter into the eye. The electric field iontophoresis device comprises a first electrode, a second electrode, and a potentiostat, which are electrically connected. The first electrode is circular and covers the eyelid skin in the flat part of the sclera and ciliary body, and the second electrode is adhered onto the back of the ear or the occipitalia. By employing a low-frequency ultrasonic and electric field iontophoresis combination mode, the transmission efficiency of the transsclerally-administrated drug is increased; the comfort level and compliance of patients are improved; and the drug bioavailability is improved.
Description
Technical field
This utility model relates to medical instruments field, and especially a kind of low frequency ultrasound associating electric field and ionic imports and carries out a back segment through sclera doser.
Background technology
Intraocular infection disease (infectious endophthalmitis etc.), immune disease (as uveitis), vascular conditions (as moist age-related macular degeneration, diabetic renal papillary necrosis etc.) are common diseases causing blindnesses, need long-term treatment.Current high molecular weight protein, nucleic acid occupies main status in the treatment of eye posterior segment disease, and how making medicine enter a back segment target site becomes the subject matter facing at present.Traditional topical eye drops and whole body operational efficiency are low, and side effect is large.Subconjunctival injection and the injection of eyeball ball week,, by passive diffusion, make some drugs enter eye inner tissue, or arrive eye inner tissue by systemic circulation.Some scholars proposes, and scleral surface is long-pending large, uses electric field and ionic leading-in technique, utilize medicine can pass through a principle for the outermost sclera barrier of eye back segment, lead to Non-Invasive means, utilize the driving effect of electric field force, increase medicine and see through the ability that sclera enters vitreous chamber.But there is following shortcoming in these medications: (1) due to sclera collagen fiber properties influence sclera drug permeability, many medicines are macromolecule polypeptide, nucleotide or albumen, have larger molecular radius (as anti-vascular endothelial growth factor etc.), very low across sclera permeability.(2) injection of ball week and subconjunctival injection exist action time short, the defect that need to repeatedly inject.(3) the electrically charged amount of medicine macromole is lower, and the efficiency that ionization imports is lower.
Intravitreal medicine (as anti-vascular endothelial growth factor or Glucocorticoid) is the main measure of controlling at present ocular angiogenesis and inflammatory reaction.Although intravitreal treatment has better therapeutic effect with respect to other route of administration, but retinopathy patient often needs long-term and treatment repeatedly, menstrual frequent intravitreal repeatedly not only exists the potential risk of complication such as causing endophthalmitis, retina shedding, vitreous hemorrhage, and brings health and spiritual misery to patient.In addition, the macromolecular drug of intravitreal is difficult to by inner limiting membrane, has affected medicine and has arrived the target site that retina photoreceptor cell，photosensory cell, pigment epithelium cell etc. are treated.Therefore, effectively medication and device in the urgent need to noinvasive clinically.
Utility model content
This utility model provides a kind of the saturating sclera controlled release drug administration of back segment device, in conjunction with hydration polymer scleral contact lens formula drug administration carrier, provide a kind of increase high molecular weight protein see through efficiency, improve patient's comfort level and doctor from property, improve bioavailability across sclera route of administration.
For realizing above object, the technical scheme that this utility model is taked is:
The saturating sclera controlled release drug administration of a back segment device, comprising: the sclera hydration polymer contact spectacles type doser of medicine carrying, and described sclera hydration polymer contact spectacles type doser is positioned in conjunctival sac; Low frequency ultrasound device, described low frequency ultrasound device comprises that one increases sclera gap to reduce medicine through the ultrasonic probe of resistance for reversibility, described ultrasonic probe is covered in orbiculus ciliaris; Electric field and ionic gatherer, be used for promoting that medicine enters ophthalmic, described electric field and ionic gatherer comprises the first electrode, the second electrode and potentiostat, described the first electrode, the second electrode all and potentiostat be electrically connected, wherein, on the eyelid skin of the rounded covering sclera orbiculus ciliaris of the first electrode position, after the second electrode paste invests ear or occipitalia, itself and the first electrode form current loop.
Low frequency ultrasound device can provide low frequency (20KHz, 1MHz), low intensity ultrasound (0-1W), ultrasound wave energy acts on orbiculus ciliaris sclera, ultrasonic energy action time is about 1 minute, by the void effect of low frequency ultrasound, change collagen fiber structure ，Shi scleral tissue gap and increase, produce temporary transient reversible biological duct and pass through for medicine, improve medicine by the infiltration efficiency of sclera.
The main body of electric field and ionic gatherer is comprised of potentiostat, and constant 0-4mA electric current can be provided, and every 0.1mA regulates unit as one, and the electric field and ionic that can arrange 0-160 minute imports the time, and each minute is one and regulates unit, convertible both positive and negative polarity.On the eyelid skin of the rounded covering sclera orbiculus ciliaris of one of them electrode position, another electrode can be attached at after ear, other positions of occipitalia or health form current loops.
Sclera hydration polymer contact spectacles type doser consists of hydration polymer, has satisfactory electrical conductivity and biological safety, is bag-shaped and is positioned in conjunctival sac, and as doser, medicine-carried also discharges medicine.
Described ultrasonic probe is hollow annular ultrasonic probe, the internal ring serious offense limbus of corneae 2mm of this hollow annular ultrasonic probe, and its internal diameter is that 16mm ，Qi bottom surface and eyelid radian match.The top of described low frequency ultrasound device is provided with a watch lamp, for patient, watches attentively, and the energy that assurance ultrasonic probe transmits, in sclera, is avoided cornea simultaneously.
The similar scleral contact lens of sclera hydration polymer contact spectacles type doser, covers whole conjunctival sac, reaches or approaches upper and lower conjunctival cul-de-sac portion, form meets leading portion sclera curvature, centered by cornea, upper and lower and temporo side is apart from limbus of corneae 8-10mm, and nasal side is apart from limbus of corneae 5mm.According to pharmaceutical properties, select corneosclera all standing type or simple sclera cover type.
Compared with prior art, tool has the following advantages this utility model:
(1) first hydration polymer as the carrier of administration, be similar to contact lens, but the contact area of scleral surface increases, according to pharmaceutical properties or the state of an illness, select whether to cover cornea, can directly put into patient's conjunctival sac, put into cosily closed eyes of rear patient, the hydration polymer carrier that has simultaneously absorbed medicine can approach sclera to maximum area, has improved the bioavailability of medicine.Hydration polymer carrier can carry two or more medicine simultaneously.
(2) adopt ultrasound, reversibility has increased sclera gap, has reduced medicine and has seen through resistance, increases the efficiency of the passive diffusion of medicine, also reduces the required electric field force of iontophoresis and administration time, has increased safety, has reduced side effect.
(3) iontophoresis, by electric field force, promotes medicine and enters ophthalmic by the sclera gap increasing, and improves the efficiency that sees through of small-molecule drug, makes the administration of macromolecular drug noinvasive become possibility.
(4) owing to being non-invasive therapy, repeatedly repetitively administered, makes drug level stable, improves drug bioavailability, improves patient's compliance and treatment comfortableness, reduces the complication causing due to the injection of ophthalmic vitreous body.
Accompanying drawing explanation
Fig. 1 is the structural representation of the electric field and ionic gatherer of the saturating sclera controlled release drug administration of this utility model eye back segment device;
Fig. 2 a is simple sclera cover type sclera hydration polymer contact spectacles type doser and eyeball fit structure schematic diagram;
Fig. 2 b is corneosclera all standing type sclera hydration polymer contact spectacles type doser and eyeball fit structure schematic diagram;
Fig. 3 is the Facad structure figure of low frequency ultrasound device;
Fig. 4 is the construction profile of low frequency ultrasound device;
Fig. 5 a is simple sclera cover type sclera hydration polymer contact spectacles type doser and the cutaway view that coordinates of eyeball and electric field and ionic gatherer;
Fig. 5 b is corneosclera all standing type sclera hydration polymer contact spectacles type doser and the cutaway view that coordinates of eyeball and electric field and ionic gatherer.
Wherein: 11, simple sclera cover type; 12, corneosclera all standing type; 2, low frequency ultrasound device; 21, ultrasonic probe; 22, watch lamp; 3, electric field and ionic gatherer; 31, the first electrode; 32, the second electrode; 33, potentiostat.
The specific embodiment
Below in conjunction with the drawings and specific embodiments, content of the present utility model is described in further details.
Embodiment:
The saturating sclera doser of back segment, imports to combine by low frequency ultrasound and electric field and ionic and makes medicine see through sclera to enter a back segment target site to reach the effect for the treatment of.It specifically comprises that 12 two kinds, the simple sclera cover type 11 shown in the electric field and ionic gatherer 3 shown in Fig. 1, Fig. 2 a and Fig. 2 b and corneosclera all standing type is loaded with the sclera hydration polymer contact spectacles type doser of medicine and the low frequency ultrasound device 2 shown in Fig. 3 and Fig. 4.
As shown in Figure 1, the main body of electric field and ionic gatherer 3 is comprised of potentiostat 33, and this potentiostat 33 can provide the constant current of 0-4mA, every 0.1mA regulates unit as one, the electric field and ionic that can arrange 0-160 minute imports the time, and each minute is one and regulates unit, convertible both positive and negative polarity.Wherein on the eyelid skin of the rounded covering sclera orbiculus ciliaris of the first electrode 31 position, the second electrode 32 can be attached at after ear, occipitalia or other positions of health form current loops.
As shown in Figure 2 a and 2 b, sclera hydration polymer contact spectacles type doser consists of hydration polymer, has satisfactory electrical conductivity and biological safety, is bag-shaped and is positioned in conjunctival sac, medicine-carried, and releasable medicaments.Its similar scleral contact lens, covers whole conjunctival sac, reaches or approaches upper and lower conjunctival cul-de-sac portion, and form meets leading portion sclera curvature, and centered by cornea, upper and lower and temporo side is apart from limbus of corneae 8-10mm, and nasal side is apart from limbus of corneae 5mm.According to pharmaceutical properties, select corneosclera all standing type 12 or simple sclera cover type 11.
As shown in Figure 3 and Figure 4, low frequency ultrasound device 2 comprises that one increases sclera gap to reduce the ultrasonic probe 21 that sees through resistance of described medicine for reversibility, the rounded orbiculus ciliaris that is covered in of ultrasonic probe 21, low frequency ultrasound device can provide low frequency (20KHz, 1MHz), low intensity ultrasound (0-1W), ultrasound ripple acts on orbiculus ciliaris sclera, ultrasonic energy action time is about 20～30 seconds, by the void effect of low frequency ultrasound, change collagen fiber structure, sclera gap is increased, produce temporary transient reversible biological duct, improve medicine by the infiltration efficiency of sclera.Ultrasonic probe 21 is hollow annular ultrasonic probe, ultrasonic probe 21 repacks hollow annular into, internal ring serious offense limbus of corneae 2mm, the eyelid radian of bottom surface and orbiculus ciliaris matches, top (being the center of hollow annular) arranges watch lamp 22, for patient, watch attentively, the energy that assurance ultrasonic probe transmits, in sclera, avoids acting on cornea simultaneously.
The present embodiment operating process is as follows:
1. topical application topical anesthetic cream before operating.
2. with a hand finger, strut upper palpebra inferior, another hands is got the sclera hydration polymer contact spectacles type doser of pastille (simple sclera cover type 11 or corneosclera all standing type 12) and is put into conjunctival sac (as shown in Fig. 5 a and 5b), twinkle for several times, sclera hydration polymer contact spectacles type doser is attached at orbiculus ciliaris, can freely open closed eyelid.
3. in eyelid surface, smear ultrasonic coupling agent, ultrasound parameter is set: (reference parameter: frequency 20KHz, the intensity 0.5W/cm such as frequency, intensity, time
2, time 30s), open watch lamp 22 patient is watched attentively, place ultrasonic probe 21 on eyelid, make ultrasonic probe 21 act on vertically downward orbiculus ciliaris, avoid cornea, start ultrasonicly, after finishing, take off ultrasonic probe 21, wipe the couplant at eyelid place.
4. the first electrode 31 adheres on the eyelid skin of sclera orbiculus ciliaris position (as shown in Fig. 5 a and 5b), after the second electrode 32 can be attached at ear or occipitalia form current loop.
5. open the switch of potentiostat 33, according to pharmaceutical properties setup times (0-160min), electrode direction (+,-), current intensity (0-4mA) and administration time, start ionization and import.
6., after ionization imports and finishes, close potentiostat 33.
7. take out sclera hydration polymer contact spectacles type doser.
Above-listed detailed description is for the illustrating of this utility model possible embodiments, and this embodiment is not in order to limit protection domain of the present utility model, does not allly depart from the equivalence that this utility model does and implements or change, all should be contained in the protection domain of this case.
Claims (6)
1. the saturating sclera controlled release drug administration of an eye back segment device, is characterized in that, it comprises:
The sclera hydration polymer contact spectacles type doser of medicine carrying, described sclera hydration polymer contact spectacles type doser is positioned in conjunctival sac;
Low frequency ultrasound device (2), described low frequency ultrasound device (2) comprises that one increases sclera gap to reduce medicine through the ultrasonic probe (21) of resistance for reversibility, described ultrasonic probe (21) is covered in orbiculus ciliaris;
Electric field and ionic gatherer (3), be used for promoting that medicine enters ophthalmic, described electric field and ionic gatherer (3) comprises the first electrode (31), the second electrode (32) and potentiostat (33), described the first electrode (31), the second electrode (32) are all connected with potentiostat (33), wherein, on the eyelid skin of the rounded covering sclera orbiculus ciliaris of the first electrode (31) position, after the second electrode (32) is attached at ear or occipitalia, itself and the first electrode (31) form current loop.
2. according to claim 1 the saturating sclera controlled release drug administration of back segment device, is characterized in that, described ultrasonic probe (21) is hollow annular ultrasonic probe, and internal ring serious offense limbus of corneae 2mm，Qi bottom surface and the eyelid radian of this hollow annular ultrasonic probe match.
3. according to claim 2 the saturating sclera controlled release drug administration of back segment device, is characterized in that, the internal diameter of described hollow annular ultrasonic probe is 16mm.
4. according to claim 2 the saturating sclera controlled release drug administration of back segment device, is characterized in that, the top of described low frequency ultrasound device (2) is provided with a watch lamp (22) of watching attentively for confession patient.
5. according to claim 1 the saturating sclera controlled release drug administration of back segment device, is characterized in that, described sclera hydration polymer contact spectacles type doser is centered by cornea, and its upper and lower and temporo side is apart from limbus of corneae 8-10mm, and nasal side is apart from limbus of corneae 5mm.
6. eye back segment saturating sclera controlled release drug administration device according to claim 1 or 5, is characterized in that, described sclera hydration polymer contact spectacles type doser is simple sclera cover type (11) or corneosclera all standing type (12).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320306408.2U CN203389001U (en) | 2013-05-30 | 2013-05-30 | Posterior eye segment transscleral controlled-release administration apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320306408.2U CN203389001U (en) | 2013-05-30 | 2013-05-30 | Posterior eye segment transscleral controlled-release administration apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203389001U true CN203389001U (en) | 2014-01-15 |
Family
ID=49900565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201320306408.2U Expired - Fee Related CN203389001U (en) | 2013-05-30 | 2013-05-30 | Posterior eye segment transscleral controlled-release administration apparatus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203389001U (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9937074B2 (en) | 2015-01-22 | 2018-04-10 | Eyegate Pharmaceuticals, Inc. | Iontophoretic contact lens |
| CN108720991A (en) * | 2018-04-28 | 2018-11-02 | 河北中尔蘑菇塑料包装有限公司 | Eye drops auxiliary device and eye-drop liquid bottle |
| CN110367927A (en) * | 2019-08-01 | 2019-10-25 | 中山大学 | Glaucoma intraocular pressure continuous detecting system and its detection method |
| CN111110439A (en) * | 2020-03-04 | 2020-05-08 | 郑州医笃筑工智能科技有限公司 | Microneedle device for retinal vein |
| CN111714793A (en) * | 2020-05-21 | 2020-09-29 | 温州医科大学附属眼视光医院 | High-precision meibomian gland diagnosis and treatment instrument |
| CN113784691A (en) * | 2019-01-09 | 2021-12-10 | 二十二十治疗学有限责任公司 | Ocular therapeutic agent delivery device |
| CN114305855A (en) * | 2021-12-29 | 2022-04-12 | 深圳大学 | Auxiliary device for eye medicine administration |
-
2013
- 2013-05-30 CN CN201320306408.2U patent/CN203389001U/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9937074B2 (en) | 2015-01-22 | 2018-04-10 | Eyegate Pharmaceuticals, Inc. | Iontophoretic contact lens |
| CN108720991A (en) * | 2018-04-28 | 2018-11-02 | 河北中尔蘑菇塑料包装有限公司 | Eye drops auxiliary device and eye-drop liquid bottle |
| CN108720991B (en) * | 2018-04-28 | 2024-06-21 | 河北中尔新材料有限公司 | Eye drop auxiliary device and eye drop bottle |
| CN113784691A (en) * | 2019-01-09 | 2021-12-10 | 二十二十治疗学有限责任公司 | Ocular therapeutic agent delivery device |
| CN110367927A (en) * | 2019-08-01 | 2019-10-25 | 中山大学 | Glaucoma intraocular pressure continuous detecting system and its detection method |
| CN111110439A (en) * | 2020-03-04 | 2020-05-08 | 郑州医笃筑工智能科技有限公司 | Microneedle device for retinal vein |
| CN111714793A (en) * | 2020-05-21 | 2020-09-29 | 温州医科大学附属眼视光医院 | High-precision meibomian gland diagnosis and treatment instrument |
| CN114305855A (en) * | 2021-12-29 | 2022-04-12 | 深圳大学 | Auxiliary device for eye medicine administration |
| CN114305855B (en) * | 2021-12-29 | 2023-10-27 | 深圳大学 | Eye administration auxiliary device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN203389001U (en) | Posterior eye segment transscleral controlled-release administration apparatus | |
| JP6768761B2 (en) | Dry eye treatment system | |
| AU2016277825B2 (en) | Nasolacrimal implants and related methods for tear stimulation | |
| AU2011355093B2 (en) | Device and method for corneal delivery of riboflavin by iontophoresis for the treatment of keratoconus | |
| US9192512B2 (en) | Device for delivering medicines by transpalpebral electrophoresis | |
| Molokhia et al. | Transscleral iontophoresis for noninvasive ocular drug delivery of macromolecules | |
| CN203370016U (en) | Posterior eye segment iontophoresis medicine dosing device | |
| Hou et al. | Study of minimally invasive radiofrequency ablation of the ciliary body for the treatment of glaucoma in rabbits | |
| JPH09266954A (en) | Therapy machine with electrode | |
| WO2015081850A1 (en) | Novel intravitreal injection drug delivery system for mouse nerve growth factor, and application thereof | |
| Wang et al. | Accessing the suprachoroidal space for therapeutic delivery | |
| AU2011252823B2 (en) | Electrode assembly for delivering a therapeutic agent into ocular tissue | |
| US20230271002A1 (en) | Hydrogel ionic circuit based devices for electrical stimulation and drug therapy | |
| CN101670146B (en) | Eye pads for treating after cataract | |
| Kotecha Rashesh et al. | PHARMA SCIENCE MONITOR | |
| Dodds | Future developments | |
| Rohilla et al. | Novel ocular drug delivery methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140115 Termination date: 20140530 |